Skip to content
Study details
Enrolling now

Continued Access to and Assessment of Long-Term Safety

Daiichi Sankyo
NCT IDNCT06174987ClinicalTrials.gov data as of Apr 2026
Phase

Phase 3

Target enrollment

50

Study length

about 4 years

Ages

18+

Locations

2 sites in FL, NC

What this study is about

This trial is testing a treatment called T-DXd in people with advanced or metastatic cancer. The goal is to see if this treatment is safe for long-term use.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take T-DXd

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: Number of Participants Reporting Treatment-emergent Adverse Events Leading to Study Drug discontinuation and/or Dose Reduction, Treatment-emergent Serious Adverse Events (TESAEs), and Treatment-emergent Adverse Events of Special Interest (AESIs)